September 24, 2016 8:42 PM ET

Biotechnology

Company Overview of Adamas Pharmaceuticals, Inc.

Company Overview

Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company’s lead product candidate is the ADS-5102 that is in Phase 3 clinical development for the treatment of levodopa-induced dyskinesia, a movement disorder associated with Parkinson’s disease; and in a Phase 2 clinical study for the treatment of symptoms associated with various sclerosis, including walking impairment. The company’s portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release ca...

1900 Powell Street

Suite 750

Emeryville, CA 94608

United States

Founded in 2000

67 Employees

Phone:

510-450-3500

Fax:

510-428-0519

Key Executives for Adamas Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 52
Total Annual Compensation: $770.0K
Senior Vice President of Product Development
Age: 63
Total Annual Compensation: $503.0K
Chief Medical Officer
Age: 47
Total Annual Compensation: $313.9K
Compensation as of Fiscal Year 2015.

Adamas Pharmaceuticals, Inc. Key Developments

Adamas Appoints Michael F. Bigham to Board of Directors

Adamas Pharmaceuticals, Inc. announced the appointment of Michael F. Bigham, Chairman and Chief Executive Officer of Paratek Pharmaceuticals, Inc., to its Board of Directors. Mr. Bigham has broad management experience with over 25 years of senior leadership in the biotechnology industry.

Allergan plc and Adamas Pharmaceuticals, Inc. Announce U.S. Availability of New Dosage Strengths for NAMZARIC Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease

Allergan plc and Adamas Pharmaceuticals, Inc. announced that all four dosage strengths of NAMZARIC (memantine and donepezil hydrochlorides) extended-release capsules that allow patients on donepezil 10 mg to start directly on NAMZARIC are now available by prescription in pharmacies throughout the U.S. NAMZARIC is a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI) for the treatment of moderate to severe Alzheimer's Disease in patients stabilized on 10 mg of donepezil hydrochloride once daily. NAMZARIC'S new indication and dosage strengths were approved by the U.S. Food and Drug Administration (FDA) in July 2016. Approximately 75% of patients diagnosed with Alzheimer's Disease are in the moderate to severe stage of the disease and yet only about one-third of these patients are treated with combination therapy. Clinical studies have shown that combination therapy with Namenda XR and an AChEI such as Aricept demonstrated significantly superior improvement in cognition and global function verses an AChEI alone. NAMZARIC will be commercially available in 30 count bottles in 7 mg/10 mg, 14 mg/10 mg, 21 mg/10 mg and 28 mg/10 mg. NAMZARIC is covered broadly by Medicare Part D prescription plans. The efficacy and safety of the coadministration of memantine HCl extended release and acetylcholinesterase inhibitors (AChEIs), including donepezil HCl, was based on the results of a randomized, double-blind, placebo-controlled trial of 677 patients with moderate to severe Alzheimer's Disease on a stable dose of AChEIs. The clinical study was not conducted with Namzaric; however, bioequivalence of Namzaric with coadministered memantine HCl extended release and donepezil HCl was demonstrated. Approximately 68% of the patients randomized to receive either memantine HCl extended release 28 mg or placebo were taking donepezil as the AChEI at Baseline and throughout the study. The results of this study, demonstrated statistically significant improvement in cognition and global function for patients treated with NAMENDA XR (memantine HCl extended release) 28 mg plus an AChEI compared to placebo plus an AChEI at 24 weeks.

Adamas Pharmaceuticals, Inc. Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia At the 4th World Parkinson Congress

Adamas Pharmaceuticals, Inc. announced details regarding two poster presentations highlighting data from EASE LID and EASE LID 3, two completed trials from the company's Phase 3 clinical program of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease, to be presented at the 4th World Parkinson Congress (WPC) being held in Portland, Oregon, September 20 to 23, 2016. Adamas Phase 3 clinical program of ADS-5102 for the treatment of LID comprises three placebo-controlled trials: EASED, EASE LID and EASE LID 3. These trials enrolled a total of 286 patients, of which 122 patients received a 340 mg dose of ADS-5102 once daily before bedtime for a pre-specified period of time. In all three trials, changes in LID versus placebo were assessed by the Unified Dyskinesia Rating Scale (UDysRS): week 8 (EASED), week 12 and week 24 (EASE LID) and week 12 (EASE LID 3). EASE LID 2, an open-label safety study open to patients from EASED, EASE LID and EASE LID 3 and to LID patients who have undergone deep brain stimulation, is ongoing.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Adamas Pharmaceuticals, Inc., please visit www.adamaspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.